TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
Lancet Respir Med 2017; 5: 291–360Vol, 5 April 2017
Report of a mission 20–24 April 2015
A survey of prevention, testing and treatment policies and practices
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med...icines for all patients with MDR-TB.
more
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...tandardised questionnaires and the Global TB Drug Facility website.
more
Framework for implementation.
The END TB Strategy.
Training for staff working at DR-TB management centres.
Training modules
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
PLOS ONE | DOI:10.1371/journal.pone.0133869 July 28, 2015, p.1-16
12 countries have a high TB estimated burden with an incidence rate more than 45 per 100 000 population They represent 88 of the cases in the Region
In 2019 the TB case detection gap in the Region was 52 500 cases